NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in High-Risk Myeloma
- Recruiting
- Dec 6, 2018
- 1 min read
Updated: Jun 13, 2022
NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
KPd
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
Sponsor:
Emory University
Collaborator:
Amgen
ClinicalTrials.gov Identifier: NCT03756896
Official Title: Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
First Posted : November 28, 2018
Click here for details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Pomalidomide
Location
United States, Georgia
